Literature DB >> 29222272

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

W Robert Liu1, Margaret A Shipp1.   

Abstract

Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveillance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near-uniform copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci, CD274/PD-L1 and PDCD1LG2/PD-L2, and copy number-dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor-positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29222272      PMCID: PMC6142542          DOI: 10.1182/asheducation-2017.1.310

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  60 in total

1.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.

Authors:  S Joos; M Küpper; S Ohl; F von Bonin; G Mechtersheimer; M Bentz; P Marynen; P Möller; M Pfreundschuh; L Trümper; P Lichter
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

3.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

4.  Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Robert A Redd; Geraldine S Pinkus; Yasodha Natkunam; Azra H Ligon; Courtney F Connelly; Christine J Pak; Christopher D Carey; Sarah E Daadi; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Margaret A Shipp; Scott J Rodig
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

5.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 6.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

7.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

8.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Authors:  Christopher D Carey; Daniel Gusenleitner; Mikel Lipschitz; Margaretha G M Roemer; Edward C Stack; Evisa Gjini; Xihao Hu; Robert Redd; Gordon J Freeman; Donna Neuberg; F Stephen Hodi; Xiaole Shirley Liu; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2017-09-11       Impact factor: 22.113

View more
  8 in total

Review 1.  Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.

Authors:  Paolo Strati; Sattva S Neelapu
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.075

2.  Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.

Authors:  Talha Badar; Narendranath Epperla; Aniko Szabo; Steven Borson; John Vaughn; Gemlyn George; Neeraj Saini; Abdul Rashid Shah; Romil D Patel; Sairah Ahmed; Nirav N Shah; Amanda F Cashen; Mehdi Hamadani; Timothy S Fenske
Journal:  Blood Adv       Date:  2020-01-14

Review 3.  Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors.

Authors:  Natalie S Grover; Nicholas Tschernia; Gianpietro Dotti; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 4.  Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.

Authors:  Huimin Ma; Xin Li; Meng Lin; Kebing Lv; Mingzhi Zhang; Xiaolong Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

5.  Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.

Authors:  Kristiina Karihtala; Suvi-Katri Leivonen; Oscar Brück; Marja-Liisa Karjalainen-Lindsberg; Satu Mustjoki; Teijo Pellinen; Sirpa Leppä
Journal:  Cancers (Basel)       Date:  2020-04-04       Impact factor: 6.639

Review 6.  FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview.

Authors:  Conrad-Amadeus Voltin; Jasmin Mettler; Jirka Grosse; Markus Dietlein; Christian Baues; Christine Schmitz; Peter Borchmann; Carsten Kobe; Dirk Hellwig
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

7.  Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.

Authors:  Markus Tiemann; Vera Samoilova; Dmitri Atiakshin; Igor Buchwalow
Journal:  BMC Res Notes       Date:  2020-03-07

8.  Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.

Authors:  Debmalya Barh; Sandeep Tiwari; Lucas Gabriel Rodrigues Gomes; Marianna E Weener; Khalid J Alzahrani; Khalaf F Alsharif; Alaa A A Aljabali; Murtaza M Tambuwala; Kenneth Lundstrom; Sk Sarif Hassan; Ángel Serrano-Aroca; Kazuo Takayama; Preetam Ghosh; Elrashdy M Redwan; Bruno Silva Andrade; Siomar de Castro Soares; Vasco Azevedo; Vladimir N Uversky
Journal:  Viruses       Date:  2021-09-25       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.